| Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells L Chung, ET Orberg, AL Geis, JL Chan, K Fu, CEDS Shields, CM Dejea, ... Cell host & microbe 23 (2), 203-214. e5, 2018 | 485 | 2018 |
| YAP is essential for treg-mediated suppression of antitumor immunity X Ni, J Tao, J Barbi, Q Chen, BV Park, Z Li, N Zhang, A Lebid, ... Cancer discovery 8 (8), 1026-1043, 2018 | 176 | 2018 |
| Interleukin 17 and senescent cells regulate the foreign body response to synthetic material implants in mice and humans L Chung, DR Maestas Jr, A Lebid, A Mageau, GD Rosson, X Wu, MT Wolf, ... Science translational medicine 12 (539), eaax3799, 2020 | 117 | 2020 |
| TRAF 6 directs FOXP 3 localization and facilitates regulatory T‐cell function through K63‐linked ubiquitination X Ni, W Kou, J Gu, P Wei, X Wu, H Peng, J Tao, W Yan, X Yang, A Lebid, ... The EMBO Journal 38 (9), e99766, 2019 | 79 | 2019 |
| The immunosuppressive niche of soft-tissue sarcomas is sustained by tumor-associated macrophages and characterized by intratumoral tertiary lymphoid structures L Chen, T Oke, N Siegel, G Cojocaru, AJ Tam, RL Blosser, J Swailes, ... Clinical Cancer Research 26 (15), 4018-4030, 2020 | 53 | 2020 |
| YAP is essential for treg-mediated suppression of antitumor immunity. Cancer Discov. 2018; 8: 1026–1043. doi: 10.1158/2159-8290 X Ni, J Tao, J Barbi, Q Chen, BV Park, Z Li, N Zhang, A Lebid, ... CD-17-1124.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 32 | |
| Type 2 immunity induced by bladder extracellular matrix enhances corneal wound healing X Wang, L Chung, J Hooks, DR Maestas Jr, A Lebid, JI Andorko, ... Science advances 7 (16), eabe2635, 2021 | 27 | 2021 |
| YAP attenuates CD8 T cell-mediated anti-tumor response A Lebid, L Chung, DM Pardoll, F Pan Frontiers in immunology 11, 524805, 2020 | 27 | 2020 |
| Induced pluripotent stem cell-derived gamma delta CAR-T cells for cancer immunotherapy MA Wallet, T Nishimura, C Del Casale, A Lebid, B Salantes, ... Blood 138, 2771, 2021 | 10 | 2021 |
| Interleukin-17 and senescence regulate the foreign body response L Chung, D Maestas Jr, A Lebid, A Mageau, GD Rosson, X Wu, MT Wolf, ... BioRxiv, 583757, 2019 | 10 | 2019 |
| Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy Y Zheng, A Lebid, L Chung, J Fu, X Wang, A Otrocol, JC Zarif, H Yu, ... Oncoimmunology 13 (1), 2297503, 2024 | 1 | 2024 |
| Screening iPSC lines for optimal characteristics of differentiation into immune effector cells for clinical programs BA Morse, A Cogburn, A Chialastri, MS Hall, O Manor, A Lebid, DH Kim, ... Cancer Research 84 (6_Supplement), 3613-3613, 2024 | | 2024 |
| Discovery of a novel Nectin4 IPSC-derived cell therapy for the treatment of solid tumors JM Carton, C Dower, M Miller, J Wheeler, S Heron, HJ Millar, D Walker, ... Cancer Research 84 (6_Supplement), 1916-1916, 2024 | | 2024 |
| Engineered expression of HLA-E and HLA-G protects iPSC-derived cells from killing by primary NK cells A Lebid, DH Kim, G Greco, H Jessup, A Suarez, S Brown, N Alexander, ... Cancer Research 84 (6_Supplement), 1320-1320, 2024 | | 2024 |
| Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunity H Yu, H Nishio, J Barbi, M Mitchell-Flack, PDA Vignali, Y Zheng, A Lebid, ... bioRxiv, 2024.01. 31.578284, 2024 | | 2024 |
| EMPOWERING IPSC-DERIVED INK CELLS WITH MULTIPLE GENE EDITS TO IMPROVE PERSISTENCE AND ANTI-TUMOR EFFICACY B Gurung, A Jethon, M Harris, S Keating, S Moros, R Genovese, ... Journal for ImmunoTherapy of Cancer 10, A280-A280, 2022 | | 2022 |
| Compositions and Methods for Generating Gamma-Delta T Cells from Induced Pluripotent Stem Cells M Wallet, T Nishimura, M Mendonca, A Lebid, B Salantes, K Santostefano, ... US Patent App. 17/657,798, 2022 | | 2022 |
| The neurotrophic factor Neuritin regulates T cell anergy and T regulatory cell function H Yu, H Nishio, J Barbi, M Mitchell-Flack, P Vignali, Y Zheng, A Lebid, ... The Journal of Immunology 208 (1_Supplement), 56.03-56.03, 2022 | | 2022 |
| Target the activin receptor 1c on CD4+ T cells to achieve anti-tumor therapeutic effects. Y Zheng, A Lebid, J Fu, C Patel, X Wang, D Pardoll The Journal of Immunology 208 (1_Supplement), 180.09-180.09, 2022 | | 2022 |
| TARGET THE ACTIVIN RECEPTOR 1C ON CD4+ T CELLS TO ACHIEVE ANTI-TUMOR THERAPEUTIC EFFECTS Y Zheng, A Lebid, A Pardoll, J Fu, C Patel, X Wang JOURNAL FOR IMMUNOTHERAPY OF CANCER 9, A679-A679, 2021 | | 2021 |
